Hepatitis B

Perz JF, Armstrong GL, Farrington LA, et al (2006) The contributions of hepatitis B virus and hepatitis C virus infection to cirrhosis and primary liver cancer worldwide. J Hepatol 45: 529–538

World Health Organisation (2002) Hepatitis B. Electronic Citation. www.who.int/csr/disease/hepatitis/HepatitisB_whocdscsrlyo2002_2.pdf

Epidemiologisches Bulletin 49/ 2007, Robert Koch Institut

Ganem D, Prince AM (2004) Hepatits B Virus Infection – Natural History and Clinical Consequences. N Engl J Med 350: 1118–1129

Petersen J. www.hepatitisandmore.de/archiv/2007-1

Scheiblauer H, Soboll H, Nick S (2006) Evaluation of 17-CE marked HBsAg-assays with respect clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 78 [Suppl 1]: 66–70

Cornberg M, et al (2007) Prophylaxe, Diagnostik und Therapie der HBV Infektion. Z Gastroenterol 45: 1–50

Pawlotsky JM (2002) Molecular diagnosis of viral hepatitis. Gastroenterology 122: 1554–1568

Han Y, Tang Q, Zhu W, et al (2008) Clinical, biochemical, immunological and virological profiles of, and differential diagnosis between, patients with acute hepatitis B and chronic hepatitis B with acute flare. J Gastroenterol Hepatol 23: 1728–1733

Hadziyannis SJ, Papatheodoridis GV (2006) Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liv Dis 26: 130–141

Impfplan Österreich. Evidenz-basierte Empfehlungen des Obersten Sanitätsrates 06-11-2007

Miyake Y (2008) Lamivudine treatment improves the prognosis of fulminant hepatitis B. Intern Med 47: 1293–1299

Chen CJ, Yang HI, Su J, et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295: 65–73

EASL International consensus conference on hepatitis B. 13–14 September, 2002, Geneva, Switzerland (2003) Consensus statement. The EASL Jury. J Hepatol 39: 3–25

Craxì A, Di Bona D, Cammà C (2003) Interferon-alpha for HBeAg-positive chronic hepatitis B. J Hepatol 39 [Suppl 1]: 99–105

Fattovich G, Brollo L, Boscaro S, et al (1989) Long-term effect of low dose recombinant interferon therapy in patients with chronic hepatitis B. J Hepatol 9: 331–337

Korenman J, Baker B, Waggoner J, et al (1991) Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 114: 629–634

Lin SM, Yu ML, Lee CM, et al (2007) Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 46: 45–52

Cooksley WG, Piratvisuth T, Lee SD, et al (2003) Peginterferon alpha-2a (40kDa): an advance in the treatment of hepatitis B. J Viral Hepat 10: 298–305

Marcellin P, Lau GK, Bonino F, et al (2004) Peginterferon alpha-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351: 1206–1217

Janssen HL, van Zonneveld M, Senturk H, et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365: 123–129

Locarnini S, Hatzakis A, Heathcote J, et al (2004) Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 9: 679–693

Chang TT, Gish RG, de Man R, et al (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354: 1001–1010

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al (2003) Adefovir Dipivoxil 438 Study Group. Adefovir Dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348: 800–807

Liaw YF, Sung JJ, Chow WC, et al (2004) Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351: 1521–1531

Dienstag JL, Schiff ER, Wright TL, et al (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341: 1256–1263

Hoofnagle JH, Doo E, Liang TJ, et al (2007) Management of hepatitis B: Summary of a clinical research workshop. Hepatology 45: 1056–1075

Peters MG, Hann HW, Martin P, et al (2004) Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 126: 91–101

Marcellin P, Heathcote EJ, Buti M, et al (2008) Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. N Engl J Med 359: 2442–2455

van Bömmel F, Zöllner B, Sarrazin C, et al (2006) Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 44: 318–325

Lai CL, Leung N, Teo EK, et al (2005) A 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis B e antigene-positivs chronic hepatitis B. Gastroenterology 129: 528–536

Chan HL, Heathcote EJ, Marcellin P, et al (2007) Treatment of hepatitis B e antigene positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 147: 745–754

Lai CL, Rosmawati M, Lao J, et al (2002) Entecavir is superior to lamuvudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 123: 1831–1838

Chang TT, Gish RG, Hadziyannis SJ, et al (2005) A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology 129: 1198–1209

Colonno R, Rose R, Baldick C, et al (2005) Entecavir two year resistance update: no resistance observed in nucleoside-naïve patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology 42 [Suppl 1]: 573–574

Lee HS, Chung YH, Lee K, et al (2006) A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic Hepatitis B. Hepatology 43: 982–988

Keeffe EB, Zeuzem S, Koff RS, et al (2007) Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 5: 890–897

Di Marco V, Marzano A, Lampertico P, et al (2004) Clinical outcome of HBe-Ag-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 40: 883–891

Samuel D, Muller R, Alexander G, et al (1993) Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 329: 1842–1847

Stärkel P, Stoffel M, Lerut J, et al (2005) Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected HBV-infected liver graft recipients. Liver Transpl 11: 1228–1234

Lok AS, McMahon BJ (2007) AASLD Practice Guidelines: chronic hepatitis B. Hepatology 45: 507–539